Altimmune, Inc. (ALT)

Market Cap	409.71M
Revenue (ttm)	20,000
Net Income (ttm)	-95.06M
Shares Out	77.01M
EPS (ttm)	-1.34
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,333,402
Open	5.57
Previous Close	5.57
Day's Range	5.30 - 5.57
52-Week Range	5.14 - 11.16
Beta	0.86
Analysts	Strong Buy
Price Target	21.00 (+294.74%)
Earnings Date	May 8, 2025

About ALT

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. The company’s lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 and is headquartered in Gaithersburg, Maryland.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1997
• Employees: 59
• Stock Exchange: NASDAQ
• Ticker Symbol: ALT
• Website: https://altimmune.com

Financial Performance

In 2024, Altimmune's revenue was $20,000, a decrease of -95.31% compared to the previous year's $426,000. Losses were -$95.06 million, 7.48% more than in 2023.

Analyst Forecast

According to 8 analysts, the average rating for ALT stock is "Strong Buy." The 12-month stock price forecast is $21.0, which is an increase of 294.74% from the latest price.

Price Target

$21.0

(294.74% upside)

Analyst Consensus: Strong Buy